The flu is estimated to cause 400,000 respiratory deaths each year on average across the world. These deaths come from pneumonia and other respiratory symptoms caused by the flu. People also die from other complications of the flu – such as a stroke or heart attack – but global estimates have not been made of their death toll. The Spanish flu caused the largest influenza pandemic in history. Yet, data on the flu is limited. With better testing, countries could improve their response to flu epidemics. It could help to rapidly identify new strains, detect epidemics early, and design better-matched vaccines to target flu strains circulating in the population.

this data set contains the vaccine coverage around the world from 2018 to 2022.

Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.

this graph was created in OurDataWorld, R , Loocker and Tableau

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fcae3bb501c71af31a491739671842d0d%2Fgraph1.png?generation=1712001396965624&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fb9bb57abd368d522f4f70edd77e44cd5%2Fgraph2.png?generation=1712001404173500&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Ffcc4718729d85efd4fb21eb4cdfb1ee3%2Fgraph3.jpg?generation=1712001411161330&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2F3a1dd72755f5473cf5f9c0758edc1dd3%2Fgraph4.png?generation=1712001416526151&alt=media" alt="">

Introduction: Seasonal influenza, often perceived as a common illness, carries a significant global burden, claiming hundreds of thousands of lives annually. Despite advancements in healthcare and vaccination efforts, the flu remains a formidable threat, particularly affecting vulnerable populations such as infants and the elderly. This article delves into the intricacies of influenza-related mortality, examining regional disparities, contributing factors, and the implications for public health.

The Global Landscape of Influenza Mortality: Data from the Global Pandemic Mortality Project II sheds light on the magnitude of influenza-related deaths, drawing from surveillance metrics spanning from 2002 to 2011. These estimates, while informative, underscore the challenge of accurately gauging mortality rates, especially in low-income countries where testing and mortality records may be lacking.

Respiratory Symptoms and Beyond: The conventional understanding of influenza-related fatalities primarily revolves around respiratory complications. Pneumonia and other respiratory ailments serve as prominent causes of death, contributing to the staggering toll of 400,000 lives claimed annually. However, it is imperative to acknowledge that the impact of influenza extends beyond respiratory symptoms. Complications such as strokes and heart attacks, though not explicitly captured in mortality estimates, further amplify the disease's lethality, warranting comprehensive preventive measures.

Vulnerability Across Age Groups: Influenza's lethality is not uniform across age demographics. Infants and the elderly emerge as the most susceptible cohorts, bearing the brunt of severe complications and mortality. Among individuals aged over 65, the mortality rate stands at approximately 31 per 100,000 in Europe alone, reflecting the disproportionate impact on older populations. The interplay of age-related factors, including weakened immune responses and underlying health conditions, exacerbates the severity of influenza outcomes among these groups.

Regional Disparities and Determinants: A notable aspect of influenza mortality lies in its disparate distribution across regions. While Europe and North America exhibit relatively lower death rates, countries in South America, Africa, and South Asia grapple with higher mortality burdens. This regional divide underscores the complex interplay of socio-economic factors, healthcare accessibility, and vaccination coverage. Poverty, inadequate healthcare infrastructure, and suboptimal vaccination rates converge to heighten vulnerability to influenza-related complications, amplifying mortality rates in resource-constrained settings.

Implications for Public Health: The revelation of significant regional differentials in influenza mortality necessitates a tailored approach to public health interventions. Strengthening healthcare systems, particularly in low-income regions, is paramount to bolstering surveillance, enhancing diagnostic capabilities, and facilitating timely interventions. Furthermore, targeted vaccination campaigns, coupled with education initiatives, hold promise in mitigating influenza's toll, especially among vulnerable populations. Addressing socio-economic disparities and bolstering healthcare resilience emerge as pivotal strategies in fortifying global defenses against seasonal influenza.

Conclusion: Seasonal influenza, often underestimated in its impact, exacts a substantial toll on global health each year. The multifaceted nature of influenza-related mortality underscores the need for a nuanced understanding and comprehensive mitigation strategies. By addressing regional disparities, prioritizing vulnerable populations, and fortifying healthcare systems, the global community can strive towards mitigating the burden of seasonal influenza, safeguarding lives, and fostering resilient health systems for generations to come.

https://fluprint.com/about/section_1.png" alt="Influenza vaccination responders">

The problem

Influenza virus has a devastating societal impact, causing up to 650,000 deaths every year worldwide. Specifically, vulnerable are children and elderly. It is estimated that 1 in 1000 children and elderly every year are hospitalized due to influenza infection. Vaccination can prevent influenza-like illnesses, and thus lower the risk of the virus outbreak. However, currently available vaccines do not always provide protection, even among otherwise-healthy people, leading to serious pandemics. Development of better vaccines depends on our understanding why current vaccines work in some individuals, while fail in others.

About dataset

The FluPRINT is the name of a unified database for a large-scale study exploring novel cellular and molecular underpinnings of successful immunity to influenza vaccines. It contains information on more than 3,000 parameters measured using mass cytometry, flow cytometry, phosphorylation-specific cytometry (phospho-flow), multiplex ELISA, clinical lab tests (hormones and complete blood count), serological profiling with hemagglutination inhibition assay, and virological tests. The dataset represents fully integrated and normalized immunology measurements from 747 individuals from eight clinical studies conducted between 2007 to 2015 at the Human Immune Monitoring Center of Stanford University. The dataset represents a unique source in terms of value and scale, which will broaden our understanding of influenza immunity.

Additional info: https://zenodo.org/record/3222451#.XOb7MaR7lPY

Citation

Tomic A, Tomic I, Dekker CL, Maecker HT and Davis MM. The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system. Sci Data, doi: 10.1038/s41597-019-0213-4, 2019. 

Monthly Cumulative Number and Percent of Persons Who Received ≥1 Influenza Vaccination Doses, by Flu Season, Age Group, and Jurisdiction

• Influenza vaccination coverage for children and adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. More information about the IIS can be found at https://www.cdc.gov/vaccines/programs/iis/about.html.

• Influenza vaccination coverage estimate numerators include the number of people receiving at least one dose of influenza vaccine in a given flu season, based on information that state, territorial, and local public health agencies report to CDC. Some jurisdictions’ data may include data submitted by tribes. Estimates include persons who are deceased but received a vaccination during the current season. People receiving doses are attributed to the jurisdiction in which the person resides unless noted otherwise. Quality and completeness of data may vary across jurisdictions. Influenza vaccination coverage denominators are obtained from 2020 U.S. Census Bureau population estimates.

• Monthly estimates shown are cumulative, reflecting all persons vaccinated from July through a given month of that flu season. Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.

• Because IIS data contain all vaccinations administered within a jurisdiction rather than a sample, standard errors were not calculated and statistical testing for differences in estimates across years were not performed.

• Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction. More information on laws and policies are found at https://www.cdc.gov/vaccines/programs/iis/policy-legislation.html.

• Coverage estimates based on IIS data are expected to differ from National Immunization Survey (NIS) estimates for children (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-coverage-race.html) and adults (https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-adult-coverage.html) because NIS estimates are based on a sample that may not be representative after survey weighting and vaccination status is determined by survey respondent rather than vaccine records or administrations, and quality and completeness of IIS data may vary across jurisdictions. In general, NIS estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions.

Seasonal influenza epidemics have a substantial public health and economic burden in the United States (US). On average, over 200,000 people are hospitalized and an estimated 23,000 people die from respiratory and circulatory complications associated with seasonal influenza virus infections each year. Annual direct medical costs and indirect productivity costs across the US have been found to average respectively at $10.4 billion and $16.3 billion. The objective of this study was to estimate the economic impact of severe influenza-induced illness on the US Veterans Affairs population. The five-year study period included 2010 through 2014. Influenza-attributed outcomes were estimated with a statistical regression model using observed emergency department (ED) visits, hospitalizations, and deaths from the Veterans Health Administration of the Department of Veterans Affairs (VA) electronic medical records and respiratory viral surveillance data from the Centers for Disease Control and Prevention (CDC). Data from VA’s Managerial Cost Accounting system were used to estimate the costs of the emergency department and hospital visits. Data from the Bureau of Labor Statistics were used to estimate the costs of lost productivity; data on age at death, life expectancy and economic valuations for a statistical life year were used to estimate the costs of a premature death. An estimated 10,674 (95% CI 8,661–12,687) VA ED visits, 2,538 (95% CI 2,112–2,964) VA hospitalizations, 5,522 (95% CI 4,834–6,210) all-cause deaths, and 3,793 (95% CI 3,375–4,211) underlying respiratory or circulatory deaths (inside and outside VA) among adult Veterans were attributable to influenza each year from 2010 through 2014. The annual value of lost productivity amounted to $27 (95% CI $24–31) million and the annual costs for ED visits were $6.2 (95% CI $5.1–7.4) million. Ninety-six percent of VA hospitalizations resulted in either death or a discharge to home, with annual costs totaling $36 (95% CI $30–43) million. The remaining 4% of hospitalizations were followed by extended care at rehabilitation and skilled nursing facilities with annual costs totaling $5.5 (95% CI $4.4–6.8) million. The annual monetary value of quality-adjusted life years (QALYs) lost amounted to $1.1 (95% CI $1.0–1.2) billion. In total, the estimated annual economic burden was $1.2 (95% CI $1.0–1.3) billion, indicating the substantial burden of seasonal influenza epidemics on the US Veterans Affairs population. Premature death was found to be the largest driver of these costs, followed by hospitalization.

Chicago residents who are up to date with influenza vaccines by ZIP Code, based on the reported home address and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE).

“Up to date” refers to individuals aged 6 months and older who have received 1+ doses of influenza vaccine during the current season, defined as the beginning of July (MMWR week 27) through the end of the following June (MMWR week 26).

Data Notes:

Weekly cumulative totals of people up to date are shown for each combination ZIP Code and age group. Note there are rows where age group is "All ages" so care should be taken when summing rows. Weeks begin on a Sunday and end on a Saturday.

Coverage percentages are calculated based on the cumulative number of people in each ZIP Code and age group who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. For ZIP Codes mostly outside Chicago, coverage percentages are not calculated because reliable Chicago-only population counts are not available. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller ZIP Codes with smaller populations. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage by geography. All coverage percentages are capped at 99%.

The Chicago Department of Public Health (CDPH) uses the most complete data available to estimate influenza vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Influenza vaccine administration is not required to be reported in Illinois, except for publicly funded vaccine (e.g., Vaccines for Children, Section 317). Individuals may receive vaccinations that are not recorded in I-CARE, such as those administered in another state, or those administered by a provider that does not submit data to I-CARE, causing underestimation of the number individuals who received an influenza vaccine for the current season.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to influenza, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=flu .

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau 2020 Decennial Census

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024 Annual Season Influenza Vaccinations - This indicator shows the percentage of adults who are vaccinated annually against seasonal influenza. For many people, the seasonal flu is a mild illness, but for some it can lead to pneumonia, hospitalization, or death. Vaccination of persons in high-risk populations is especially important to reduce their risk of severe illness or death. Link to Data Details

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Demographic Trends and Health Outcomes in the U.S

Inequalities,Risk Factors and Access to Care

By Data Society [source]

About this dataset

This dataset contains key demographic, health status indicators and leading cause of death data to help us understand the current trends and health outcomes in communities across the United States. By looking at this data, it can be seen how different states, counties and populations have changed over time. With this data we can analyze levels of national health services use such as vaccination rates or mammography rates; review leading causes of death to create public policy initiatives; as well as identify risk factors for specific conditions that may be associated with certain populations or regions. The information from these files includes State FIPS Code, County FIPS Code, CHSI County Name, CHSI State Name, CHSI State Abbreviation, Influenza B (FluB) report count & expected cases rate per 100K population , Hepatitis A (HepA) Report Count & expected cases rate per 100K population , Hepatitis B (HepB) Report Count & expected cases rate per 100K population , Measles (Meas) Report Count & expected cases rate per 100K population , Pertussis(Pert) Report Count & expected case rate per 100K population , CRS report count & expected case rate per 100K population , Syphilis report count and expected case rate per 100k popuation. We also look at measures related to preventive care services such as Pap smear screen among women aged 18-64 years old check lower/upper confidence intervals seperately ; Mammogram checks among women aged 40-64 years old specified lower/upper conifence intervals separetly ; Colonosopy/ Proctoscpushy among men aged 50+ measured in lower/upper limits ; Pneumonia Vaccination amongst 65+ with loewr/upper confidence level detail Additionally we have some interesting trend indicating variables like measures of birth adn death which includes general fertility ratye ; Teen Birth Rate by Mother's age group etc Summary Measures covers mortality trend following life expectancy by sex&age categories Vressionable populations access info gives us insight into disablilty ratio + access to envtiromental issues due to poor quality housing facilities Finally Risk Factors cover speicfic hoslitic condtiions suchs asthma diagnosis prevelance cancer diabetes alcholic abuse smoking trends All these information give a good understanding on Healthy People 2020 target setings demograpihcally speaking hence will aid is generating more evience backed policies

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

What the Dataset Contains

This dataset contains valuable information about public health relevant to each county in the United States, broken down into 9 indicator domains: Demographics, Leading Causes of Death, Summary Measures of Health, Measures of Birth and Death Rates, Relative Health Importance, Vulnerable Populations and Environmental Health Conditions, Preventive Services Use Data from BRFSS Survey System Data , Risk Factors and Access to Care/Health Insurance Coverage & State Developed Types of Measurements such as CRS with Multiple Categories Identified for Each Type . The data includes indicators such as percentages or rates for influenza (FLU), hepatitis (HepA/B), measles(MEAS) pertussis(PERT), syphilis(Syphilis) , cervical cancer (CI_Min_Pap_Smear - CI_Max\Pap \Smear), breast cancer (CI\Min Mammogram - CI \Max \Mammogram ) proctoscopy (CI Min Proctoscopy - CI Max Proctoscopy ), pneumococcal vaccinations (Ci min Pneumo Vax - Ci max Pneumo Vax )and flu vaccinations (Ci min Flu Vac - Ci Max Flu Vac). Additionally , it provides information on leading causes of death at both county levels & national level including age-adjusted mortality rates due to suicide among teens aged between 15-19 yrs per 100000 population etc.. Furthermore , summary measures such as age adjusted percentage who consider their physical health fair or poor are provided; vulnerable populations related indicators like relative importance score for disabled adults ; preventive service use related ones ranging from self reported vaccination coverage among men40-64 yrs old against hepatitis B virus etc...

Getting Started With The Dataset

To get started with exploring this dataset first your need to understand what each column in the table represents: State FIPS Code identifies a unique identifier used by various US government agencies which denote states . County FIPS code denotes counties wi...

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

Chicago residents who are up to date with influenza vaccines by Healthy Chicago Equity Zone (HCEZ), based on the reported address, race-ethnicity, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE).

Healthy Chicago Equity Zones is an initiative of the Chicago Department of Public Health to organize and support hyperlocal, community-led efforts that promote health and racial equity. Chicago is divided into six HCEZs. Combinations of Chicago’s 77 community areas make up each HCEZ, based on geography. For more information about HCEZs including which community areas are in each zone see: https://data.cityofchicago.org/Health-Human-Services/Healthy-Chicago-Equity-Zones/nk2j-663f

“Up to date” refers to individuals aged 6 months and older who have received 1+ doses of influenza vaccine during the current season, defined as the beginning of July (MMWR week 27) through the end of the following June (MMWR week 26).

Data notes:

Weekly cumulative totals of people up to date are shown for each combination of race-ethnicity and age group within an HCEZ. Note that each HCEZ has a row where HCEZ is “Citywide” and each HCEZ has a row where age is "All" and race-ethnicity is “All Race/Ethnicity Groups” so care should be taken when summing rows. Weeks begin on a Sunday and end on a Saturday.

Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity within an HCEZ) who are up to date, divided by the estimated number of people in that subgroup. Population counts are from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group within an HCEZ. All coverage percentages are capped at 99%. Summing all race/ethnicity group populations to obtain citywide populations may provide a population count that differs slightly from the citywide population count listed in the dataset. Differences in these estimates are due to how community area populations are calculated. The Chicago Department of Public Health (CDPH) uses the most complete data available to estimate influenza vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Influenza vaccine administration is not required to be reported in Illinois, except for publicly funded vaccine (e.g., Vaccines for Children, Section 317). Individuals may receive vaccinations that are not recorded in I-CARE, such as those administered in another state, or those administered by a provider that does not submit data to I-CARE, causing underestimation of the number individuals who received an influenza vaccine for the current season.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to influenza, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=flu .

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau 2020 Decennial Census

Context

The 2009 swine flu pandemic was an influenza pandemic that lasted for about 19 months, from January 2009 to August 2010, and the second of two pandemics involving H1N1 influenza virus.

Content

1. data.csv - contains day by day country wise no. of cases & deaths from 4th April to 6th July 2009

Note

• Although the pandemic went on for more than 2 years the data is only from 24th April 2009 to 6th July 2009.
• Because the countries were no longer required to test and report individual cases from 6th July 2009.
• So that day by day data from 6th July 2009 is not available.

Acknowledgements / Data Source

https://www.who.int/csr/disease/swineflu/updates/en/

Collection methodology

https://github.com/imdevskp/h1n1_data_webscrapping

Cover Photo

Photo from CDC Blog https://blogs.cdc.gov/publichealthmatters/2019/04/h1n1/

Similar Datasets

• COVID-19 - https://www.kaggle.com/imdevskp/corona-virus-report
• MERS - https://www.kaggle.com/imdevskp/mers-outbreak-dataset-20122019
• Ebola Western Africa 2014 Outbreak - https://www.kaggle.com/imdevskp/ebola-outbreak-20142016-complete-dataset
• H1N1 | Swine Flu 2009 Pandemic Dataset - https://www.kaggle.com/imdevskp/h1n1-swine-flu-2009-pandemic-dataset
• SARS 2003 Pandemic - https://www.kaggle.com/imdevskp/sars-outbreak-2003-complete-dataset
• HIV AIDS - https://www.kaggle.com/imdevskp/hiv-aids-dataset

Influenza virus is the cause of the death of millions of people with about 3–4 pandemics every hundred years in history. It also turns into a seasonal disease, bringing about approximately 5–15% of the population to be infected and 290,000–650,000 people to die every year. These numbers reveal that it is necessary to be on the alert to work towards influenza in order to protect public health. There are FDA-approved antiviral drugs such as oseltamivir and zanamivir recommended by the World Center for Disease Prevention. However, after the recent outbreaks such as bird flu and swine flu, increasing studies have shown that the flu virus has gained resistance to these drugs. So, there is an urgent need to find new drugs effective against this virus. This study aims to investigate new drug candidates targeting neuraminidase (NA) for the treatment of influenza by using computer aided drug design approaches. They involve virtual scanning, de novo design, rational design, docking, MD, MMGB/PBSA. The investigation includes H1N1, H5N1, H2N2 and H3N2 neuraminidase proteins and their mutant variants possessing resistance to FDA-approved drugs. Virtual screening consists of approximately 30 thousand molecules while de novo and rational designs produced over a hundred molecules. These approaches produced three lead molecules with binding energies for both non-mutant (-34.84, −59.99 and −60.66 kcal/mol) and mutant (-40.40, −58.93, −76.19 kcal/mol) H2N2 NA calculated by MM-PBSA compared with those of oseltamivir −25.64 and −18.40 respectively. The results offer new drug candidates against influenza infection. Communicated by Ramaswamy H. Sarma

Health and Safety Code section 1288.7(a) requires California acute care hospitals to offer influenza vaccine free of charge to all healthcare providers (HCP) or sign a declination form if a HCP chooses not to be vaccinated. Hospitals must report HCP influenza vaccination data to the California Department of Public Health (CDPH), including the percentage of HCP vaccinated. CDPH is required to make this information public on an annual basis [Health and Safety Code section 1288.8 (b)].

California acute care hospitals are required to offer free influenza vaccine to HCP. Hospital HCP must receive an annual vaccine or sign a declination form. Hospitals collect vaccination data for all HCP physically working in the hospital for at least one day during influenza season, regardless of clinical responsibility or patient contact. Hospitals report HCP vaccination rates to the California Department of Public Health (CDPH) and CDPH publishes the hospital results annually. CDPH reports data separately for hospital employees, licensed independent practitioners such as physicians, other contract staff, and trainees and volunteers (Health and Safety Code section 1288.7-1288.8).

Detailed information about the variables included in each dataset are described in the accompanying data dictionaries for the year of interest.

For general information about NHSN, surveillance definitions, and reporting requirements for HCP influenza vaccination, please visit: https://www.cdc.gov/nhsn/hps/vaccination/index.html

To link the CDPH facility IDs with those from other Departments, including OSHPD, please reference the "Licensed Facility Cross-Walk" Open Data table at: https://data.chhs.ca.gov/dataset/licensed-facility-crosswalk.

For information about healthcare personnel influenza vaccinations in California hospitals, please visit: https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/HealthcarePersonnelInfluenzaVaccinationReportingInCA_Hospitals.aspx

Context

In this dataset, we will take a look at vaccination, a key public health measure used to fight infectious diseases. Vaccines provide immunization for individuals, and enough immunization in a community can further reduce the spread of diseases through "herd immunity."

As of the update of this dataset, vaccines for the COVID-19 virus are still under development and not yet available. The dataset will instead revisit the public health response to a different recent major respiratory disease pandemic.Beginning in spring 2009, a pandemic caused by the H1N1 influenza virus, colloquially named "swine flu," swept across the world. Researchers estimate that in the first year, it was responsible for between 151,000 to 575,000 deaths globally.

A vaccine for the H1N1 flu virus became publicly available in October 2009. In late 2009 and early 2010, the United States conducted the National 2009 H1N1 Flu Survey. This phone survey asked respondents whether they had received the H1N1 and seasonal flu vaccines, in conjunction with questions about themselves. These additional questions covered their social, economic, and demographic background, opinions on risks of illness and vaccine effectiveness, and behaviors towards mitigating transmission. A better understanding of how these characteristics are associated with personal vaccination patterns can provide guidance for future public health efforts.

Content

The goal is to predict how likely individuals are to receive their H1N1 and seasonal flu vaccines. Specifically, you'll be predicting two probabilities: one for h1n1_vaccine and one for seasonal_vaccine as well as any sophisticates EDAs.

Each row in the dataset represents one person who responded to the National 2009 H1N1 Flu Survey and there are two target variables:

• h1n1_vaccine: Whether respondent received H1N1 flu vaccine.
• seasonal_vaccine: Whether respondent received seasonal flu vaccine.

Both are binary variables: 0 = No; 1 = Yes. Some respondents didn't get either vaccine, others got only one, and some got both. This is formulated as a multilabel (and not multiclass) problem.

You are provided a dataset with 36 columns. The first column respondent_id is a unique and random identifier. The remaining 35 features are described below(For all binary variables: 0 = No; 1 = Yes) :

• age_group - Age group of respondent.
• education - Self-reported education level.
• race - Race of respondent.
• sex - Gender of respondent.
• income_poverty - Household annual income of respondent with respect to 2008 Census poverty thresholds.
• marital_status - Marital status of respondent.
• rent_or_own - Housing situation of respondent.
• employment_status - Employment status of respondent.
• h1n1_concern - Level of concern about the H1N1 flu. 0 = Not at all concerned; 1 = Not very concerned; 2 = Somewhat concerned; 3 = Very concerned.
• h1n1_knowledge - Level of knowledge about H1N1 flu. 0 = No knowledge; 1 = A little knowledge; 2 = A lot of knowledge.
• behavioral_wash_hands - Has frequently washed hands or used hand sanitizer. (binary)
• behavioral_large_gatherings - Has reduced time at large gatherings. (binary)
• behavioral_antiviral_meds - Has taken antiviral medications. (binary)
• behavioral_avoidance - Has avoided close contact with others with flu-like symptoms. (binary)
• behavioral_face_mask - Has bought a face mask. (binary)
• behavioral_outside_home - Has reduced contact with people outside of own household. (binary)
• behavioral_touch_face - Has avoided touching eyes, nose, or mouth. (binary)
• doctor_recc_h1n1 - H1N1 flu vaccine was recommended by doctor. (binary)
• doctor_recc_seasonal - Seasonal flu vaccine was recommended by doctor. (binary)
• chronic_med_condition - Has any of the following chronic medical conditions: asthma or an other lung condition, diabetes, a heart condition, a kidney condition, sickle cell anemia or other anemia, a neurological or neuromuscular condition, a liver condition, or a weakened immune system caused by a chronic illness or by medicines taken for a chronic illness. (binary)
• child_under_6_months - Has regular close contact with a child under the age of six months. (binary)
• health_worker - Is a healthcare worker. (binary)
• health_insurance - Has health insurance. (binary)
• opinion_h1n1_vacc_effective - Respondent's opinion about H1N1 vaccine effectiveness. 1 = Not at all effective; 2 = Not very effective; 3 = Don't know; 4 = Somewhat effective; 5 = Very effective.
• opinion_h1n1_risk - Respondent's opinion about risk of getting sick with H1N1 flu without vaccine. 1 = Very Low; 2 = Somewhat low; 3 = Don't know; 4 = Somewhat high; 5 = Very high.
• opinion_h1n1_sick_from_vacc - Respondent's worry of getting sick from taking H1N1 vaccine. 1 = Not at all worried; 2 = Not very worried; 3 = Don't know; 4 = Somewhat worried; 5 = Very wo...

This study will determine if an experimental avian flu (bird flu) vaccine is safe, whether it has side effects and if it can stimulate an immune response in people. The vaccine being tested in this study is made from DNA (genetic material) that codes for an influenza protein called hemagglutinin 5 (H5), which is based on the protein from the bird flu virus. The study will determine if the body creates resistance or immunity to the H5 protein. The hope is that an immune response to this protein may protect against bird flu virus infection. Healthy people between 18 and 60 years old who have been vaccinated with the current season's influenza vaccine may be eligible for this study. Participants are randomly assigned to receive injections of one of the following: 1) study vaccine at 1 mg dose, 2) study vaccine at 4 mg dose, or 3) placebo (salt-water solution). They receive three injections about 4 weeks apart in the upper arm muscle. Participants record their temperature and symptoms at home for 5 days after each injection, either on a diary card or electronically using the Internet, and report any side effects to a study physician or nurse as soon as possible. They return to NIH for clinic visits every 2 weeks for the first 12 weeks, then at week 26 and at week 42 to check for health changes or problems. Blood is drawn at all visits and urine samples are collected through week 10. If a participant develops serious side effects, the study physician may decide that he or she should not receive any further injections. However, all participants are asked to continue the follow-up visits even if they do not get the full set of three injections.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by sex, age group, and jurisdiction of occurrence.

The Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is a network that conducts, active, population-based surveillance for laboratory confirmed hospitalizations associated with Influenza, COVID-19, and RSV. The RESP-NET platforms have overlapping surveillance areas and use similar methods to collect data. Hospitalization rates show how many people in the surveillance area are hospitalized with influenza, COVID-19, and RSV compared to the total number of people residing in that area.

Data will be updated weekly. Data are preliminary and subject to change as more data become available.